Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications
Implication of ncRNAs in cellular signaling pathways related to cancer immune resistance. NcRNAs can affect the efficacy of immunotherapy through modulation of cancer cell ferroptosis. miR-21-3p accelerates IFN-γ-mediated ferroptosis by downregulating TXNRD1 to impel lipid peroxidation. NEAT1 increases MIOX expression by sponging miR-362-3p. This event enhances ROS production and decreases the intracellular levels of NADPH and GSH, eventually leading to cancer cell ferroptosis. Moreover, NEAT1 reinforces the anticancer potency of ferroptosis activators erastin and RSL3. LINC01085 inhibits the phosphorylation of TBK1 by abating its interaction with GSK3β. Accordingly, LINC01085 blocks the activation of the STING/MAVS/IRF3 signaling pathway, resulting in downregulation of NF-κB and PD-L1 and decreased production of type I/III IFNs. LINC01085 can act in synergy with anti-PD-L1 treatment. PD-L1, programmed cell death-ligand 1; PD-1, programmed cell death protein-1; IFN-γ, interferon-γ; MAVS, mitochondrial antiviral signaling protein; STING, stimulator of interferon genes; GSK3β, glycogen synthase kinase 3β; TKB1, TANK-binding kinase 1; IRF3, interferon regulatory factor 3; NF-κB, nuclear factor-κB; TXNRD1, thioredoxin reductase 1; RSL3, RAS-selective lethal 3; MIOX, myo-inositol oxygenase; GSH, glutathione; NAPDH, nicotinamide adenine dinucleotide phosphate; GPX4, glutathione peroxidase 4; GSR, glutathione reductase; GSSG, oxidized glutathione; ROS, reactive oxygen species.
Publication
Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications. (2023) Man Wang, et al. Front Immunol. 2023;14:1268745. Figure: F3.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | IRF3 | IRF3 | ncbigene_symbol | IRF3 | 3661 |
| Homo sapiens | Primates | STING | STING | ncbigene_synonym | STING1 | 340061 |
| Homo sapiens | Primates | MAVS | MAVS | ncbigene_symbol | MAVS | 57506 |
| Homo sapiens | Primates | GSK3B | GSK3B | ncbigene_symbol | GSK3B | 2932 |
| Homo sapiens | Primates | LINC01085 | LINC01085 | ncbigene_symbol | LINC01085 | 152742 |
| Homo sapiens | Primates | TBK1 | TBK1 | ncbigene_symbol | TBK1 | 29110 |
| Homo sapiens | Primates | NF-KB | NF-KB | ncbigene_synonym | NFKB1 | 4790 |
| Homo sapiens | Primates | CD8+ | CD8 | ncbigene_synonym | CD8A | 925 |
| Homo sapiens | Primates | CD8+ | CD8 | famplex_relations | CD8B | 926 |
| Homo sapiens | Primates | PD-1 | PD-1 | ncbigene_synonym | PDCD1 | 5133 |
| Homo sapiens | Primates | PD-1 | PD-1 | ncbigene_synonym | RPL17 | 6139 |
| Homo sapiens | Primates | PD-1 | PD-1 | ncbigene_synonym | RPL17-C18orf32 | 100526842 |
| Homo sapiens | Primates | PD-L1 | PD-L1 | ncbigene_synonym | CD274 | 29126 |
| Homo sapiens | Primates | NEAT1 | NEAT1 | ncbigene_symbol | NEAT1 | 283131 |
| Homo sapiens | Primates | MIOX | MIOX | ncbigene_symbol | MIOX | 55586 |
| Homo sapiens | Primates | GPX4 | GPX4 | ncbigene_symbol | GPX4 | 2879 |
| Homo sapiens | Primates | GSR | GSR | ncbigene_symbol | GSR | 2936 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Glutamate | NA | |||
| Cystine | Cystine | mesh:D003553 | cystine | chebi:17376 |
| Cysteine | Cysteine | mesh:D003545 | cysteine | chebi:15356 |
| GSSG | Glutathione Disulfide | mesh:D019803 | glutathione disulfide | chebi:17858 |
| GSH NAPDH | Glutathione | mesh:D005978 | glutathione | chebi:16856 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|